arrow_back Trending Legislation
Share share

Better Drugs: Patient Voice Stronger in Approval Process

This act ensures that patient experiences, such as their opinions on medications and treatment outcomes, will be given greater weight when new drugs are approved. This means the Food and Drug Administration (FDA) will have to consider more closely how drugs affect the daily lives of those who take them, potentially leading to safer and more effective therapies.
Key points
Increased influence of patient feedback on new drug approval decisions.
The Food and Drug Administration (FDA) will be required to detail how patient data influenced drug risk-benefit assessments.
Potential for faster access to drugs that are genuinely needed and well-tolerated by patients.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
BENEFIT Act of 2021
Print number: HR 4472
Sponsor: Rep. Matsui, Doris O. [D-CA-6]
Process start date: 2021-07-16
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Better Drugs: Patient Voice Stronger in Approval Process

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 4472.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-16.

What are the main provisions?

Key points include:

  • Increased influence of patient feedback on new drug approval decisions.
  • The Food and Drug Administration (FDA) will be required to detail how patient data influenced drug risk-benefit assessments.
  • Potential for faster access to drugs that are genuinely needed and well-tolerated by patients.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-6].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 4472

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health